


a.) Amendment to the Claims:


1. (Original) A pharmaceutical composition which comprises (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



or a pharmaceutically acceptable salt thereof, and

(b) an anticholinergic agent.

2. (Original) The pharmaceutical composition according to Claim 1, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

3. (Currently Amended) The pharmaceutical composition according to Claim 1 or 2, wherein the anticholinergic agent ~~is/are selected from any one of or more than~~ is at least one of the following: group consisting of oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

Claims 4-6 (Cancelled).

7. (Currently Amended) A kit which comprises (a) a first component containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and

(b) a second component containing ~~an~~ at least one anticholinergic agent.

8. (Original) The kit according to Claim 7, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):




(Ia)

9. (Currently Amended) The kit according to Claim 7 or 8, wherein the anticholinergic agent ~~is/are selected from any one of or more than~~ is at least one of the following: group consisting of oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

Claims 10-12 (Cancelled).


13. (Currently Amended) 3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



(I)


or a pharmaceutically acceptable salt thereof, ~~which may be administered together or separately at an interval with an anticholinergic agent.~~

14. (Original) 3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof according to Claim 13, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



Claim 15 (Cancelled)


16. (Currently Amended) A pharmaceutical composition which comprises, as an active ingredient, 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, ~~which may be administered together or separately at an interval with an anticholinergic agent~~ together with a pharmaceutically acceptable carrier.


17. (Original) The pharmaceutical composition according to Claim 16, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



(Ia)

18. (Currently Amended) The pharmaceutical composition according to Claim 16 or 17, ~~wherein the anticholinergic agent is/are selected from any one of or more than one of the following:~~ further comprising at least one anticholinergic agent selected from the group consisting of oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

19. (Currently Amended) A method for treating overactive bladder, which comprises administering (a) 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, and (b) an anticholinergic agent, which said (a) and (b) may be administered together or separately at an interval.

20. (Original) The method for treating overactive bladder according to Claim 19, wherein 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-

dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide is (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide represented by Formula (Ia):



21. (Currently Amended) The method for treating overactive bladder according to Claim 19 or 20, wherein the anticholinergic agent ~~is/are selected from any one of or more than one of the following:~~ is at least one member selected from the group consisting of oxybutynin, propiverine, tolterodine, darifenacin, temiverine, trospium chloride, tiotropium, oxytropium, ipratropium, flutropium, atropine, scopolamine, solifenacin and KRP-197, and pharmaceutically acceptable salts thereof.

22. (New) The method for treating overactive bladder according to Claim 19 or 20, comprising administering plural anticholinergic agents separately or at an interval.